New hope for lung cancer patients too weak for standard chemo?

NCT ID NCT04297605

Recruiting now Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with advanced non-small cell lung cancer who are not well enough for standard strong chemotherapy. It tests a combination of one chemotherapy drug and an immunotherapy drug (pembrolizumab) to see if it is safe and helps shrink tumors. About 60 participants will take part, and the goal is to find a treatment option that is both tolerable and effective for this group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL-CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Rochester
NOT_YET_RECRUITING

Rochester, New York, 14642, United States
University of Rochester
RECRUITING

Rochester, New York, 14642, United States

Contact Email: •••••@•••••

Contact